These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9848638)

  • 1. Stability of iron dextran (DexFerrum) in peritoneal dialysis bags.
    Manley HJ; Grabe DW; Bailie GR; Norcross ML
    Perit Dial Int; 1998; 18(5):538-40. PubMed ID: 9848638
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
    Hood SA; O'Brien M; Higgins R
    Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond.
    Mittman N
    Am J Kidney Dis; 1999 Jul; 34(1):173-6. PubMed ID: 10401035
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintaining iron balance with total-dose infusion of intravenous iron dextran.
    Case G
    ANNA J; 1998 Feb; 25(1):65-8. PubMed ID: 9543911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 7. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
    Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
    QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A protocol for administering intravenous iron dextran in peritoneal dialysis patients.
    Huff J
    ANNA J; 1998 Aug; 25(4):419-23. PubMed ID: 9791315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran.
    Freter S; Davidman M; Lipman M; Bercovitch D
    Am J Nephrol; 1997; 17(5):477-9. PubMed ID: 9382172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies.
    Sloand JA; Shelly MA; Erenstone AL; Schiff MJ; Talley TE; Dhakal MP
    Perit Dial Int; 1998; 18(5):522-7. PubMed ID: 9848632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
    Sepandj F; Jindal K; West M; Hirsch D
    Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron products.
    Johnson CA; Mason NA; Bailie GR
    ANNA J; 1999 Oct; 26(5):522-4. PubMed ID: 10776081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The iron story: red smoke and magnetism?
    Wish JB
    Nephrol News Issues; 2014 Feb; 28(2):2-3. PubMed ID: 24649743
    [No Abstract]   [Full Text] [Related]  

  • 15. Goodbye oral iron therapy?
    Forman E
    Pediatr Blood Cancer; 2013 Nov; 60(11):1731. PubMed ID: 23900795
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
    Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
    Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
    Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K
    Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the use of parenteral iron in end-stage renal disease patients: focus on issues of infection and cardiovascular disease. Introduction.
    Owen WF
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S1-2. PubMed ID: 10516368
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.